Armed with fresh trial data, Catabasis doubles down on Duchenne drug
Regrouping after a trial setback involving its lead drug for Duchenne muscular dystrophy, Cambridge-based Catabasis Pharmaceuticals is forging ahead with a late-stage study, touting new data on Wednesday hinting that the treatment can improve the lives of boys with the muscle-wasting disease.
Catabasis (Nasdaq: CATB) previously announced in January that a Phase 2 study of the drug, called edasalonexent, had failed to meet its primary goal — significantly reducing leg muscle inflammation compared…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Boys | Health Management | Muscular Dystrophy | Reflex Sympathetic Dystrophy | Study